Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma

Jennifer J.G. Welch; Cindy L. Schwartz; Meghan Higman; Lu Chen; Allen Buxton; Jennifer A. Kanakry; Samir B. Kahwash; Robert E. Hutchison; Debra L. Friedman; Richard F. Ambinder

Blood Advances (Apr 2017)

Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma

Jennifer J.G. Welch,
Cindy L. Schwartz,
Meghan Higman,
Lu Chen,
Allen Buxton,
Jennifer A. Kanakry,
Samir B. Kahwash,
Robert E. Hutchison,
Debra L. Friedman,
Richard F. Ambinder

Affiliations

Jennifer J.G. Welch: Hasbro Children's Hospital, Alpert Medical School, Brown University, Providence, RI;
Cindy L. Schwartz: MD Anderson Cancer Center, University of Texas, Houston, TX;
Meghan Higman: Roswell Park Cancer Institute/UBMD Pediatrics, Buffalo, NY;
Lu Chen: Children's Oncology Group, Monrovia, CA;
Allen Buxton: Children's Oncology Group, Monrovia, CA;
Jennifer A. Kanakry: Experimental Transplantation and Immunology Branch, National Institutes of Health, Bethesda, MD;
Samir B. Kahwash: Nationwide Children's Hospital, Columbus, OH;
Robert E. Hutchison: Department of Pathology, State University of New York, Upstate Medical University, Syracuse, NY;
Debra L. Friedman: Vanderbilt-Ingram Cancer Center, Nashville, TN
Richard F. Ambinder: Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD; Richard F. Ambinder, CRB1 Room 389, 1650 Orleans St, Baltimore, MD 21287;

Journal volume & issue: Vol. 1, no. 11
pp. 681 – 684

Abstract

Read online

Abstract: Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children's Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.

Published in Blood Advances

ISSN: 2473-9529 (Print); 2473-9537 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine
Website: https://ashpublications.org/bloodadvances

About the journal